Vertex Pharmaceuticals is expected to report Q2 2026 revenue of $3.23 billion and EPS of 4.30, while its current price of $477.10 sits significantly below the analyst consensus target of $554.91.
Investors are primarily focused on the commercial trajectory of the CASGEVY gene therapy and the newly launched non-opioid pain treatment, JOURNAVX, as the company seeks to diversify its revenue beyond cystic fibrosis.
While the core CF franchise remains a robust cash engine, markets are monitoring the patient switch rate from the blockbuster Trikafta to the next-generation "vanza triple" therapy, ALYFTREK.
Recent performance has been marked by successful pediatric label expansions and a strategic $10 billion acquisition of Crinetics Pharmaceuticals to bolster the company's long-term endocrinology pipeline.